ecampus

The US (Food and Drug Administration) (Food and Drug Administration) has asked makers of all anti depression medicate drugs to change the existing “black box” labels on their products to warn about increased risk of suicidality (suicidal thinking and behaviour) among young adults aged 18 to 24 in the first few weeks of a cure.

The Food and Drug Administration has also asked the drug companies to revise the existing warning to show there is no evidence this risk exists for adults over 24, and indeed for those aged 65 and older the scientific data suggests the suicidality risk is decreased.

The update request is welcomed by psychiatrists and otherness health professionals.

The American Psychiatric Association (APA) said:

“The Food and Drug Administration’s new labeling acknowledges, for the first time, that untreated depression puts group at risk for suicide.”

They said studies showed that the old label issued in 2004 was associated with a steep drop in use of anti depression medicates and was followed by an increase in the rate of suicide “reversing a decade-long decline in suicide deaths in the United States”.

The Food and Drug Administration said the emphasis on the new labels should be that depression and otherness serious psychiatric illnesses are themselves the most important causes of suicide.

Director of Food and Drug Administration’s Center for Drug Evaluation and Research, Dr Steven Galson said yesterday that:

“Today’s actions represent Food and Drug Administration’s commitment to a high level of post-marketing evaluation of drug products.”

“Depression and otherness psychiatric disorders can have significant consequences if not appropriately treated. Antidepressant drugs benefit many patients, but it is important that doctors and patients are aware of the risks,” he explained.

The Food and Drug Administration recommends that group who are currently taking anti depression medicates should not stop taking them as a result of hearing this news. If you are worried about it, talk to your doctor, is their advice.

The warning revision applies to all anti depression medicates and comes in the wake of controlled trials that showed a reasonably consistent risk of suicidality across most of the anti depression medicate drug categories. The Food and Drug Administration said that the evidence does not support excluding any anti depression medicate medication from this update request.

This update request follows the labelling changes made in 2005 to warn of increased suicidality in children and adolescents taking anti depression medicates.

Since then, the Food and Drug Administration undertook a comprehensive review of 295 drug trials examining the risk of suicidality among adults taking anti depression medicates.

The trials included over 77,000 adult patients with major depressive disorder (MDD) and otherness psychiatric conditions.

The results was that in December last year, the Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee said labels should be changed to tell doctors about the increased risk of suicidality among younger adults taking anti depression medicates.

The Committee also said the labels should remind doctors that the disorders themselves present the greater risk, and that among older adults the anti depression medicates do not carry the suicidality risk and have an apparent beneficial effect.

The Food and Drug Administration is preparing drafts of patient guides and wording for the labels. The manufacturers have 30 days to submit their own versions for Food and Drug Administration review.

The drugs affected include:

— Anafranil (clomipramine)
— Asendin (amoxapine)
— Aventyl ( Nortriptyline(Pamelor))
— Celexa (citalopram hydrobromide)
— Cymbalta (duloxetine)
— Desyrel (trazodone hydrochloride)
— Elavil (amitriptyline)
— Effexor (Effexor(Venlafaxine) hydrochloride)
— Emsam (selegiline)
— Etrafon (perphenazine/amitriptyline)
— fluvoxamine maleate
— Lexapro (escitalopram hydrobromide)
— Limbitrol (chlordiazepoxide/amitriptyline)
— Ludiomil (maprotiline)
— Marplan (isocarboxazid)
— Nardil (phenelzine sulfate)
— nefazodone hydrochloride
— Norpramin (desipramine hydrochloride)
— Pamelor ( Nortriptyline(Pamelor))
— Parnate (tranylcypromine sulfate)
— Paxil ( Paxil(Paroxetine) hydrochloride)
— Pexeva ( Paxil(Paroxetine) mesylate)
— Prozac (fluoxetine hydrochloride)
— Remeron (mirtazapine)
— Sarafem (fluoxetine hydrochloride)
— Seroquel (quetiapine)
— Sinequan (doxepin)
— Surmontil (trimipramine)
— Symbyax (olanzapine/fluoxetine)
— Tofranil (imipramine)
— Tofranil-PM (imipramine pamoate)
— Triavil (perphenazine/amitriptyline)
— Vivactil (protriptyline)
— Wellbutrin (bupropion hydrochloride)
— Zoloft (sertraline hydrochloride)
— Zyban (bupropion hydrochloride)

The APA said:

“We believe the new label, which still contains important warning information, reminds physicians and patients that anti depression medicates save lives. Physicians and patients need all the facts in order to make appropriate, informed decisions about any proposed course of a cure.”

Click here for Food and Drug Administration.

Click here for A-Z of drugs on the Internet Drug Index (RxList, run by WebMD, commercial site).

Written by: Catharine Paddock
Writer: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Todayviagra soft tabs 120 pills